Skip to content

A multi-center clinical study: Immune surveillance of Patients with Severe Sepsis based on single-cell sequencing

A multi-center clinical study: Immune surveillance of Patients with Severe Sepsis based on single-cell sequencing

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040296
Enrollment
Unknown
Registered
2020-11-27
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Healthy control group:None
Sepsis group:None

Sponsors

Zhongshan Hospital Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Healthy control group: (1) Aged 18 to 65 years old; (2) No chronic underlying diseases; (3) There is no infectious disease this time; (4) Obtain informed consent and sign informed consent; 2. Sepsis group: (1) Aged 18 to 65 years old; (2) Sepsis patients who meet the Criteria of Sepsis 3.0 according to the 2016 international Sepsis expert consensus, namely, for patients with infection or suspected infection, when the Sepsis related sequential organ failure SOFA score increases by >=2 points from baseline; (3) The septic shock standard was not reached according to Sepsis 3.0 standard; (4) Obtain informed consent and sign informed consent; 3. Septic shock group (1) Aged 18 to 65 years old; (2) Sepsis patients who meet the Criteria of Sepsis 3.0 proposed by the 2016 international Sepsis expert consensus, that is, for patients with infection or suspected infection, when the Sepsis related sequential organ failure SOFA score increases by >=2 points from baseline; (3) Meet the septic shock standard according to Sepsis3.0 standard: in the case of appropriate fluid replenishment still need to use the booster treatment to maintain MAP>=65mmHg; Patients with septic shock with blood lactic acid level of >2mmol/L; (4) Obtain informed consent and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with congenital immune deficiency, tumor, rheumatic immune system disease, blood system disease, hormone or immunomodulatory drugs within 1 month after organ transplantation; 2. Patients suffering from uncontrollable neurological, mental illness or mental disorder, poor compliance and inability to cooperate; 3. patients who have joined other clinical trials; 4. Circumstances that the researcher considers inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
SOFA score;

Secondary

MeasureTime frame
APACHE II score;PSI score;

Countries

China

Contacts

Public ContactWU DUOJIAO

Zhongshan Hospital Fudan University

wuduojiao@126.com+86 13764145925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026